To sign up for Analytiqa's free weekly newsletter, please enter your details below.
Analytiqa will not share this information with third parties.
Group sales up 5% at constant exchange rates1, 1% in Swiss francs
Pharmaceuticals Division sales up 4%, driven by oncology (HER2-positive breast cancer medicines, Avastin) and strong growth in immunology (Actemra, Xolair)
Diagnostics Division sales up 6%, driven by Professional Diagnostics and Molecular Diagnostics
Core earnings per share increased by 5% to 14.29 Swiss francs; up 7% excluding one-time double charge of the US Branded Prescription Drug fee2
Board proposes dividend increase of 3% to 8.00 Swiss francs, 28th consecutive year of dividend growth
Outlook for 2015: Sales expected to grow low-to mid-single digit, at constant exchange rates. Core earnings per share targeted to grow at constant exchange rates ahead of sales.
Roche expects to further increase its dividend in Swiss francs.